Adrienne G. Randolph, M.D., M.Sc., Associate Professor of Anaesthesia, Harvard Medical School and Senior Associate in Critical Care at Boston Children's Hospital, commented, "Acute Respiratory Failure is a major cause for the admission of children into the intensive care unit. There is a clear unmet medical need for better therapeutic options to help these children. A new medical therapy that reduces the duration of mechanical ventilation for patients with Acute Respiratory Failure would be considered clinically important."
Premature babies, or those that have passed meconium in utero depend on Sufraxin. It's either DSCO's drug or an animal derived alternative. Discovery owns this market segment. I expect quarter over quarter revenue growth year after year since there isn't an alternative.